Sol Gel Technologies Ltd - Asset Resilience Ratio
Sol Gel Technologies Ltd (SLGL) has an Asset Resilience Ratio of 58.16% as of June 2026. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See working capital position of Sol Gel Technologies Ltd to evaluate short-term liquidity relative to the company's equity base.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2017–2025)
This chart shows how Sol Gel Technologies Ltd's Asset Resilience Ratio has changed over time. For the complete balance sheet picture, see SLGL asset base.
Liquid Assets Composition Over Time
This chart breaks down Sol Gel Technologies Ltd's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. Explore SLGL long-term investment intensity to see how much of total assets are deployed in long-term investments.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0% |
| Short-term Investments | $31.27 Million | 58.16% |
| Total Liquid Assets | $31.27 Million | 58.16% |
Asset Resilience Insights
- Very High Liquidity: Sol Gel Technologies Ltd maintains exceptional liquid asset reserves at 58.16% of total assets.
- This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
- The company has significant short-term investments, indicating active treasury management.
Sol Gel Technologies Ltd Industry Peers by Asset Resilience Ratio
Compare Sol Gel Technologies Ltd's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
ALK-Abelló A/S
CO:ALK-B |
Biotechnology | 0.98% |
|
Mirum Pharmaceuticals Inc
NASDAQ:MIRM |
Biotechnology | 6.89% |
|
Xiamen Amoytop Biotech Co Ltd
SHG:688278 |
Biotechnology | 4.69% |
|
BB Biotech AG
SW:BION |
Biotechnology | 92.97% |
|
Soleno Therapeutics Inc
NASDAQ:SLNO |
Biotechnology | 20.15% |
|
Nanobiotix
NASDAQ:NBTX |
Biotechnology | 4.71% |
|
Wuhan Keqian Biology Co Ltd
SHG:688526 |
Biotechnology | 19.42% |
|
Beijing Konruns Pharmaceutical Co Ltd
SHG:603590 |
Biotechnology | 10.55% |
Annual Asset Resilience Ratio for Sol Gel Technologies Ltd (2017–2025)
The table below shows the annual Asset Resilience Ratio data for Sol Gel Technologies Ltd.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-12-31 | 43.34% | $12.97 Million | $29.92 Million | +30.96pp |
| 2024-12-31 | 12.38% | $4.44 Million | $35.85 Million | -54.93pp |
| 2023-12-31 | 67.31% | $30.48 Million | $45.29 Million | +21.89pp |
| 2022-12-31 | 45.42% | $21.18 Million | $46.63 Million | +11.95pp |
| 2021-12-31 | 33.47% | $23.16 Million | $69.19 Million | -39.30pp |
| 2020-12-31 | 72.77% | $43.05 Million | $59.16 Million | +5.94pp |
| 2019-12-31 | 66.83% | $40.97 Million | $61.30 Million | -15.92pp |
| 2018-12-31 | 82.75% | $57.66 Million | $69.68 Million | +56.63pp |
| 2017-12-31 | 26.12% | $4.00 Million | $15.31 Million | -- |
About Sol Gel Technologies Ltd
Sol-Gel Technologies Ltd., together with its subsidiary Sol-Gel Technologies Inc., develops topical dermatological drugs for patients with severe skin conditions in Israel, China, Switzerland, Canada, the United States and internationally. The company offers Twyneo, a once-daily, non-antibiotic topical cream for the treatment of acne vulgaris; and Epsolay, a once-daily topical cream for the treat… Read more